Coronary Artery Disease, Diabetes
Conditions
Brief summary
The objective of the study is to compare angiographic and clinical performance of Abluminus DES+ versus Everolimus-eluting DES in patients with diabetes mellitus.
Detailed description
The present clinical investigation is designed as a prospective, multicentre, national, randomized, open label, 2-arm parallel group, pilot trial comparing Abluminus DES+ versus Everolimus-eluting DES on Late Lumen Loss and clinical outcomes in diabetic patients undergoing Percutaneous Coronary Intervention. A total of 165 patients will be recruited and randomized in the two groups in a 2:1 ratio at up to 6-8 Italian sites. After index procedure, patients will be followed up by angiographic follow-up at 9 months and clinical follow-up at 12 months. The study design is open label, since it is not possible to blind the investigators as to the stent type. However the members of the Event Adjudication Committee will be blinded to the patient. assignment. All medical records, source documentation and event information collected for the adjudication process will be blinded to treatment assignment. In addition the primary endpoint will be independently evaluated by the Core-Lab which will be blinded as to group assignment.
Interventions
DEVICEdevice implantation during coronary angioplasty
device implantation during coronary angioplasty
Sponsors
Mediolanum Cardio Research
Fondazione Evidence per Attività e Ricerche Cardiovascolari ONLUS
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
The members of the Event Adjudication Committee will be blinded to the patient assignment. All medical records, source documentation and event information collected for the adjudication process will be blinded to treatment assignment
Intervention model description
Randomized multi-centre controlled clinical trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age\>18 2. Diabetes mellitus 3. Documented CAD: stable or unstable angina, Non-ST segment MI, silent ischemia or positive functional study 4. PCI considered appropriate and feasible 5. Culprit de novo lesion in a native coronary artery with significant stenosis (\>50% by visual estimate) eligible for stent implantation (no limitation on the number of treated lesions, vessel and lesion length); 6. Patient provides written informed consent 7. Patient agrees to all required follow-up procedures and visits. 8. Target lesion suitable for PCI with DES diameter between 2.5 and 4.0 mm.
Exclusion criteria
1. The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, aspirin, clopidogrel, ticlopidine, sirolimus, everolimus, and/or contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled); 2. Any contraindication to the implant of the Abluminus DES+ 3. Subject is pregnant, nursing, or is a woman of child-bearing potential who is not surgically sterile, 2 years postmenopausal, or does not consistently use effective methods of contraception;; 4. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions; 5. Previous coronary intervention on target vessel in the 3-months prior to enrollment; 6. Non-cardiac co-morbid conditions with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment); 7. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period; 8. Previously documented left ventricular ejection fraction (LVEF) \<30%; 9. Evident cardiogenic shock before randomization; 10. Patients with left main stem stenosis (\>50% by visual estimate); 11. In-stent restenosis; 12. ST-segment elevation MI; 13. Chronic total occlusion. 14. Culprit lesion to a Saphenous Vein graft
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| In-stent neointimal volume | 9-month follow-up | In-stent neointimal volume, measured with OCT, following PCI with Abluminus DES+ compared with in-stent neointimal volume following PCI with Everolimus-eluting DES. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Target Lesion Failure | 12 months | This will be a composite of cardiac death, target-vessel MI, and clinically indicated TLR |
| Stent thrombosis | 12 months | This is defined according to classification proposed by the Academic Research Consortium |
| Cardiac death | 12 months | Any death due to proximate cardiac cause (eg, MI, fatal arrhythmia), unwitnessed death and death of unknown cause, and all procedure-related deaths, including those related to concomitant treatment, will be classified as cardiac death. |
| Target vessel myocardial infarction | 12 months | Any MI that, irrespective of the time after the index procedure, is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause33 Type of acute MI is classified according to the Joint ESC/ACCF/AHA/ WHF Joint Task Force for the Universal Definition of Myocardial Infarction |
| Neointimal area | 9-month follow-up | Neointimal area, calculated at the site of minimal lumen area measured with OCT. |
| Device success at 24 hours | 24 hours | deployment of the assigned stents without system failure or device-related complication |
| Lesion success | 24 hours | Attainment of \<50% residual stenosis of the target lesion using post-PCI |
| Procedural success | 24 hours | Lesion success without the occurrence of Major Adverse Cardiac Events during the hospital stay |
| Target lesion revascularization | 12 months | repeat revascularization will be defined as any repeat PCI or new coronary artery bypass graft (CABG) surgery within the first year post-PCI. |
Countries
Italy
Outcome results
None listed